Amifostine

VARIOUS

Key facts

Amifostine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1995. DrugCentral lists 2 molecular targets, including DRD3 and ALPL. Recorded indications include Prevention of Cancer Chemotherapy-Induced Renal Impairment and Prevention of Xerostomia Secondary to Radiation Therapy.

• Approval status: ofp (first approved 1995 by the FDA).
• Molecular targets: DRD3 and ALPL (2 listed in DrugCentral).
• Indications: Prevention of Cancer Chemotherapy-Induced Renal Impairment and Prevention of Xerostomia Secondary to Radiation Therapy.
• ATC code: V03AF05 (Detoxifying agents for antineoplastic treatment).
• Molecular formula: C5H15N2O3PS; molecular weight 214.22 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Prevention of Cancer Chemotherapy-Induced Renal Impairment
• Prevention of Xerostomia Secondary to Radiation Therapy

Off-label uses (5)

• Chemotherapy-induced neutropenia
• Drug-induced mucositis
• Myelodysplastic syndrome
• Prevention of Chemotherapy-Induced Neurotoxicity
• Prevention of Radiation Therapy-Induced Mucositis

Contraindications (12)

• Breastfeeding (mother)
• Cerebrovascular accident
• Chronic heart failure
• Conduction disorder of the heart
• Dehydration
• Hypocalcemia
• Hypovolemia
• Low blood pressure
• Myocardial ischemia
• Nausea
• Transient ischemic attack
• Vomiting

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
D(3) dopamine receptor	DRD3	unknown	Ki 6.18
Alkaline phosphatase, tissue-nonspecific isozyme	ALPL	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1995-12-08	FDA	—	CLINIGEN HLTHCARE	Yes

ATC classification

ATC code	Therapeutic hierarchy
V03AF05	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Mucosal inflammation	195.7
Laryngeal pain	168.2
Pyrexia	134.5
Hypotension	103.1
Chills	101.2
Nausea	79.3
Dehydration	76.5
Rash	69.1
Vomiting	67.5
Soft tissue disorder	63.4
Injection site erythema	60.7
Radiation skin injury	59.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Amifostine is on its molecule page.

• Molecular formula: C₅H₁₅N₂O₃PS
• Molecular weight: 214.22 g/mol
• CAS number: 20537-88-6
• InChIKey: JKOQGQFVAUAYPM-UHFFFAOYSA-N
• PubChem CID: 2141

NCCCNCCSP(O)(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Amifostine used for?

DrugCentral lists the following indications for Amifostine: Prevention of Cancer Chemotherapy-Induced Renal Impairment and Prevention of Xerostomia Secondary to Radiation Therapy.

How does Amifostine work?

Its molecular targets in DrugCentral include DRD3 and ALPL.

When was Amifostine first approved?

Amifostine was first approved by the FDA in 1995.

What is the chemical formula of Amifostine?

Amifostine has the molecular formula C5H15N2O3PS and a molecular weight of 214.22 g/mol.

Sources

• DrugCentral drug card 156 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1006 — compound record and bioactivity
• PubChem CID 2141 — chemical identifiers
• DrugBank DB01143 — drug record
• FDA UNII M487QF2F4V — substance identity
• DailyMed: FDA labels for Amifostine — current prescribing information (label search)
• UniProt P35462 (DRD3) — target protein
• UniProt P05186 (ALPL) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.